Company registration number SC128038 (Scotland)
CREO MEDICAL UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
A9 Accountancy Limited
Chartered Accountants
Elm House
Cradlehall Business Park
Inverness
United Kingdom
IV2 5GH
CREO MEDICAL UK LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
4
1,012,584
1,225,760
Tangible assets
5
41,895
64,314
1,054,479
1,290,074
Current assets
Stocks
1,552,911
888,816
Debtors
6
5,800,527
5,554,665
Cash at bank and in hand
2,945,008
1,029,737
10,298,446
7,473,218
Creditors: amounts falling due within one year
7
(2,539,649)
(1,881,000)
Net current assets
7,758,797
5,592,218
Net assets
8,813,276
6,882,292
Capital and reserves
Called up share capital
8
2,701,654
2,701,654
Share premium account
19,761
19,761
Profit and loss reserves
6,091,861
4,160,877
Total equity
8,813,276
6,882,292

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 14 August 2026 and are signed on its behalf by:
Mr L I Collantes Nino
Director
Company registration number SC128038 (Scotland)
CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Creo Medical UK Limited is a private company limited by shares incorporated in Scotland. The registered office is Ledingham Chalmers LLP, Ord House, Cradlehall Business Park, Inverness, IV2 5GH.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. T he company has therefore taken advantage of e xemptions from the following disclosure requirements:

- Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;

- Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;

- Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;

- Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.

The financial statements of the company are consolidated in the financial statements of Creo Medical Spain S.L. These consolidated financial statements are available from its registered office, CL Poligono Industrial Comarca I (C/ A, D22), 31160, Orcoyen, Spain.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from the sale of medical consumables (including disposable medical products and related supplies) is recognised at the point in time when:

The goods have been dispatched to the customer or delivered, depending on the contractual delivery terms;

The customer has obtained control of the goods; and

There are no significant outstanding performance obligations.

CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 3 -
1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
10 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20%-33% straight line
Fixtures and fittings
20%-33% straight line
Computers
20%-30% straight line
Motor vehicles
25% straight line
Demonstration Stock
33%-100% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 6 -
1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
9
9
CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 7 -
4
Intangible fixed assets
Goodwill
Software
Total
£
£
£
Cost
At 1 January 2025 and 31 December 2025
2,148,215
5,171
2,153,386
Amortisation and impairment
At 1 January 2025
922,455
5,171
927,626
Amortisation charged for the year
213,176
-
0
213,176
At 31 December 2025
1,135,631
5,171
1,140,802
Carrying amount
At 31 December 2025
1,012,584
-
0
1,012,584
At 31 December 2024
1,225,760
-
0
1,225,760
CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
5
Tangible fixed assets
Plant and equipment
Fixtures and fittings
Computers
Motor vehicles
Demonstration Stock
Total
£
£
£
£
£
£
Cost
At 1 January 2025
82,670
53,438
1,027
183,149
228,405
548,689
Additions
1,343
-
0
-
0
18,667
-
0
20,010
At 31 December 2025
84,013
53,438
1,027
201,816
228,405
568,699
Depreciation and impairment
At 1 January 2025
82,670
53,438
1,027
132,212
215,028
484,375
Depreciation charged in the year
161
-
0
-
0
36,705
5,563
42,429
At 31 December 2025
82,831
53,438
1,027
168,917
220,591
526,804
Carrying amount
At 31 December 2025
1,182
-
0
-
0
32,899
7,814
41,895
At 31 December 2024
-
0
-
0
-
0
50,937
13,377
64,314
CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 9 -
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
1,470,285
2,004,004
Other debtors
4,330,242
3,550,661
5,800,527
5,554,665
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
1,428,628
126,618
Taxation and social security
553,041
1,024,072
Other creditors
557,980
730,310
2,539,649
1,881,000
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
2,701,654
2,701,654
2,701,654
2,701,654
9
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its profit for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Paul Capewell FCA CA
Statutory Auditor:
A9 Accountancy Limited
Date of audit report:
18 August 2026
10
Financial commitments, guarantees and contingent liabilities

The total amount of guarantees not included in the balance sheet is £9,819 (2024 - £16,819).

CREO MEDICAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
11
Related party transactions

Section 33.1A exemption

The company has taken advantage of the exemption with FRS 102 Section 33 paragraph 33.1A, not to disclose transactions entered into between two or more members of the group, as the company is a wholly owned subsidiary of the group to which it is party to the transactions, except for those which are not considered to be under normal market conditions.

12
Parent company

The company's immediate parent is Creo Medical Spain S.L.:

PG. Ind.

Comarca I, C. A, 22

31160

Pamplona

Navarra

Spain

The ultimate parent is Micro-Tech (Nanjing) Co., Ltd:

No. 10

Gaoke 3rd Road

National Hi-Tech Zone

Nanjing

China

210032

2025-12-31 2025-01-01 false false false 18 August 2026 CCH Software CCH Accounts Production 2026.200 No description of principal activity Mr L I Collantes Nino Mr C Gulliford Mr R J Rees SC128038 2025-01-01 2025-12-31 SC128038 2025-12-31 SC128038 2024-12-31 SC128038 core:Goodwill 2025-12-31 SC128038 core:ComputerSoftware 2025-12-31 SC128038 core:Goodwill 2024-12-31 SC128038 core:ComputerSoftware 2024-12-31 SC128038 core:PlantMachinery 2025-12-31 SC128038 core:FurnitureFittings 2025-12-31 SC128038 core:ComputerEquipment 2025-12-31 SC128038 core:MotorVehicles 2025-12-31 SC128038 core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment 2025-12-31 SC128038 core:PlantMachinery 2024-12-31 SC128038 core:FurnitureFittings 2024-12-31 SC128038 core:ComputerEquipment 2024-12-31 SC128038 core:MotorVehicles 2024-12-31 SC128038 core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment 2024-12-31 SC128038 core:WithinOneYear 2025-12-31 SC128038 core:WithinOneYear 2024-12-31 SC128038 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 SC128038 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 SC128038 core:ShareCapital 2025-12-31 SC128038 core:ShareCapital 2024-12-31 SC128038 core:SharePremium 2025-12-31 SC128038 core:SharePremium 2024-12-31 SC128038 core:RetainedEarningsAccumulatedLosses 2025-12-31 SC128038 core:RetainedEarningsAccumulatedLosses 2024-12-31 SC128038 core:ShareCapitalOrdinaryShareClass1 2025-12-31 SC128038 core:ShareCapitalOrdinaryShareClass1 2024-12-31 SC128038 bus:Director1 2025-01-01 2025-12-31 SC128038 core:Goodwill 2025-01-01 2025-12-31 SC128038 core:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 SC128038 core:ComputerSoftware 2025-01-01 2025-12-31 SC128038 core:PlantMachinery 2025-01-01 2025-12-31 SC128038 core:FurnitureFittings 2025-01-01 2025-12-31 SC128038 core:ComputerEquipment 2025-01-01 2025-12-31 SC128038 core:MotorVehicles 2025-01-01 2025-12-31 SC128038 core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment 2025-01-01 2025-12-31 SC128038 2024-01-01 2024-12-31 SC128038 core:Goodwill 2024-12-31 SC128038 core:ComputerSoftware 2024-12-31 SC128038 2024-12-31 SC128038 core:PlantMachinery 2024-12-31 SC128038 core:FurnitureFittings 2024-12-31 SC128038 core:ComputerEquipment 2024-12-31 SC128038 core:MotorVehicles 2024-12-31 SC128038 core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment 2024-12-31 SC128038 core:CurrentFinancialInstruments 2025-12-31 SC128038 core:CurrentFinancialInstruments 2024-12-31 SC128038 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 SC128038 bus:OrdinaryShareClass1 2025-12-31 SC128038 bus:OrdinaryShareClass1 2024-12-31 SC128038 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 SC128038 bus:FRS102 2025-01-01 2025-12-31 SC128038 bus:Audited 2025-01-01 2025-12-31 SC128038 bus:Director2 2025-01-01 2025-12-31 SC128038 bus:Director3 2025-01-01 2025-12-31 SC128038 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 SC128038 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP